Results represent 3 independent experiments using primary human cells and are presented as mean fold change ± SE relative to untreated controls. Separate control data for the 5 and 10 ng/mL conditions reflect separate qRT-PCR runs from the same experiment. Comparable data were observed using an immortalized cell line. * = p < 0.01 for the TGF-β3 condition versus TGF-β1 or β2, and between doses for each isoform. All TGF-β treatment conditions exhibited significant differences compared to untreated controls for both genes of interest (for clarity of presentation, these comparisons are not denoted by *). Figure S4 . TGF-β3 demonstrates moderate cross-regulation of endogenous TGF-β1 and β2 expression in human vocal fold fibroblasts. (A) Treatment with 10 ng/mL TGF-β3 induced less endogenous TGF-β1 transcription than treatment with TGF-β1 or β2. (B) Treatment with 10 ng/mL TGF-β3 induced less endogenous TGF-β2 transcription than treatment with TGF-β1 or β2. (C) Treatment with TGF-β1, β2 or β3 had no effect on endogenous TGF-β3 transcription. Results represent 3 independent experiments using primary human cells and are presented as mean fold change ± SE relative to untreated controls. Separate control data for the 5 and 10 ng/mL conditions reflect separate qRT-PCR runs from the same experiment. Comparable data were observed using an immortalized cell line. * = p < 0.01 for the TGF-β3 condition versus TGF-β1 or β2, and between doses for each isoform; n.s. = no significant differences. All TGF-β treatment conditions in panels A and B exhibited significant differences compared to untreated controls for both genes of interest (for clarity of presentation, these comparisons are not denoted by *). Representative high-magnification images of rat vocal fold lamina propria showing cell-specific immunostaining patterns for the TGF-β1, TGF-β3 and CD68 primary antibodies, and matrix-specific staining patterns for the collagen, type III and lysyl oxidase primary antibodies used in this study. (B) Representative negative control images for the complete immunostaining protocol with omission of the secondary antibody incubation step. (C) Representative negative control images for the complete immunostaining protocol with omission of the primary antibody incubation step. Additional positive and negative control data for anti-TGF-β1 and anti-TGF-β3, the two non-commercial antibodies used in this study, have been previously reported (Flanders et al., 1989 (Flanders et al., , 1991 . Scale bar = 10 µm. 
